The Rise and Fall of Top Holdings: McGuire Investment Group, LLC Q4 2022 vs. Q1 2023

In the ever-changing world of investments, it is crucial to keep track of the trends and movements of the top holdings of various funds. McGuire Investment Group, LLC is a notable player in the game, and their Q4 2022 vs. Q1 2023 13F Holdings Comparison sheds light on the changes in their portfolio. This post will analyze the top 10 increases and decreases in holdings and explore the potential reasons behind these shifts.

Introduction:

McGuire Investment Group, LLC manages over $626.0 million in assets, with a focus on technology, healthcare, and consumer goods sectors. In Q4 2022, their top three holdings were AMD with 45.63%, QCOM with 22.31%, and LRCX with 5.12%, while in Q1 2023, their top three holdings were AMD with 45.49%, QCOM with 21.60%, and LRCX with 5.49%. The slight changes in the top three holdings indicate the overall stability of the fund's strategy. However, in the following sections, we will examine the significant increases and decreases in other holdings.

Body:

The top increase in holdings from Q4 2022 to Q1 2023 was in CTLT, with a massive 43.8% increase in shares and a 44.13% increase in value. Catalent Inc. is a pharmaceutical contract development and manufacturing organization that has been on the rise due to increasing demand for manufacturing COVID-19 vaccines. McGuire Investment Group, LLC's decision to increase its holdings in CTLT might be due to the optimistic forecast of the industry.

The second-largest increase in holdings was in CRSP with a 64.2% increase in shares and a 64.46% increase in value. CRISPR Therapeutics is a gene-editing company, and its stock price has been skyrocketing over the past year. The market is bullish on gene-editing technology, and McGuire Investment Group, LLC might be betting on its future growth.

On the other hand, the top decrease in holdings was in GNOM, with a drastic 64.1% decrease in shares and a 66.15% decrease in value. Global X Genomics & Biotechnology ETF was the only ETF in the portfolio, and its decrease might demonstrate a shift in the fund's strategy away from ETFs. Or the reason behind the decrease could be due to the fund's assessment of the market, deciding that the current value of the ETF does not align with their investment goals.

The fourth-largest decrease was in JNJ, with a 15.7% decrease in shares and a 17.97% decrease in value. Johnson & Johnson has been involved in multiple lawsuits over the past few years, including the recent opioid crisis. The negative press could have played a role in McGuire Investment Group, LLC's decision to reduce their holdings.

Conclusion:

McGuire Investment Group, LLC's Q4 2022 vs. Q1 2023 13F Holdings Comparison demonstrates how their fund's holdings have shifted due to various factors. The steady top three holdings, AMD, QCOM, and LRCX, reinforce the fund's stable strategy. While the significant increases in holdings in CTLT and CRSP might indicate their optimism in the pharmaceutical and gene-editing industries, respectively. Finally, the decreases in holdings of GNOM and JNJ showcase the possible shift in the fund's strategy away from ETFs and away from companies with negative press. The calculation of these decisions is a part of McGuire Investment Group, LLC's never-ending job to ensure a fruitful investment strategy.